Trump gave 18 pharma giants 60 days to match US drug prices with global lows or face federal action. Letters outlined MFN pricing, direct-to-patient sales, and price parity for Medicaid. Despite the pressure, retail sentiment turned bullish for stocks like ABBV, LLY, BMY, and NVO, with high message volume on Stocktwits.